Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03218085 · ClinicalTrials.gov registry record

Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract

A clinical trial, sponsored by University of Minnesota.

Completed
Registry status
28
Enrollment target

NCT03218085 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 28 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03218085 has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
28 participants
Enrollment target

Study Summary

Cervical biopsies will be collected from women aged 18 and over whom are virally suppressed and taking tenofovir as part of their antiretroviral therapy regimen. Blood plasma, peripheral blood mononuclear cells (PBMC), and cervicovaginal swabs will also be collected. Drug concentrations, hormone concentrations, inflammatory cytokines, and vaginal microbiome will be evaluated to understand the role of hormones, inflammation, and the microbiome in modulating drug efficacy in the female genital tract.

Interventions

  • DRUG Tenofovir
  • DRUG Emtricitabine

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2017-07-14
Est. Completion 2024-02-15

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT03218085

The ClinicalTrials.gov registry entry for NCT03218085 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Tenofovir is the first listed.

NCT03218085 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03218085 about?

NCT03218085 is a clinical study titled "Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract". Cervical biopsies will be collected from women aged 18 and over whom are virally suppressed and taking tenofovir as part of their antiretroviral therapy regimen. Blood plasma, peripheral blood mononuclear cells (PBMC), and cervicovaginal swabs will also be collected. Drug concentrations, hormone con...

What is the current status of trial NCT03218085?

This trial is currently completed. The enrollment target is 28 participants. The study started on 2017-07-14. Estimated completion is 2024-02-15.

What interventions are being tested in trial NCT03218085?

The interventions under investigation include: Tenofovir (DRUG), Emtricitabine (DRUG).

Who is sponsoring clinical trial NCT03218085?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.